Steritas is proud to announce two significant additions to its advisory board.  Zuwen Kuang and David Jayne, MD join an advisory board already comprised of Paul Brunetta, MD; Mike Broxson, MSPH MBA; and Paul Schulz, MA.

Zuwen Kuang is a skilled and experienced digital healthcare executive with a proven track record of success in the field of data and analytics, with extensive experience in building enterprise-scale big data platforms as well as delivering advanced analytics solutions and digital interoperability capabilities as the Global Head of Data and Analytics at Fresenius Medical Care.

“Zuwen brings exceptional intellectual insight and rigor to our engineering and data insight efforts at a time when we are completely revamping our platform architecture to be stateless and more nimble. Her commitment to Steritas at this stage of our development is incredibly exciting as she has had an illustrious career as a world thought leader in this area. 

Her infectious enthusiasm for developing and implementing data-driven solutions that enable precision medicine and value-based care will help guide Steritas’ next stage of development,” commented Martha Stone, CEO of Steritas on Ms Kuang’s appointment.

Dr David Jayne is a clinical nephrologist practicing in Cambridge, UK where he directs a severe inflammatory disease service that has supported more than 5,000 patients (mainly vasculitis and lupus) over the last 20 years.

“Dr Jayne adds enormous international insight as one of the developers of the Steritas GTI and in addition to being a world renowned researcher and clinician, has an incredible strategic mind that will help guide our efforts to support global health systems measure, monitor and minimize the impacts of steroid-toxicity.

From the beginning, Dr Jayne has been a champion of GTI and the importance of measuring steroid-toxicity. I feel very lucky he has accepted a position on our advisory board,” commented Mrs Stone. 

These two additions complement the exceptional talent already part of the advisory board.

• Dr Brunetta is a physician and clinical researcher and is currently the Head of Clinical and Translational Science at Sana Biotechnology, advancing cell and gene therapies into the clinic.
• Mike Broxson is CEO of Tennyson Advisory LLC, a consulting firm providing biopharma client business, corporate development strategy, and transactions advisory services.
• Mr Schulz has served in a number of senior positions in both the for-profit and nonprofit sectors and is currently the Executive Director for the Martha's Vineyard Community Foundation